ERYTHROPOETIN STIMULATES TISSUE REPAIR IN EXPERIMENTAL WOUNDS
DOI:
https://doi.org/10.31082/1728-452X-2020-219-2220-9-10-17-22Keywords:
erythropoietin, EPO, angiogenesis, wound treatmentAbstract
The efficacy of recombinant human erythropoietin (EPO) is being studied in the context of wound management. The ability of EPO to stimulate cell proliferation was found, which is of great importance in the complex process of wound healing.
The aim of this study is to evaluate the results of using EPO for wound healing in a rat model.
Material and methods. We examined 24 wounds simulated in the interscapular region of a rat, which were divided into 2 groups: a group with standard treatment, a group with EPO treatment at a dosage of 400 IU/kg, s/c. Planimetry of the wound was performed at the appointed time. Also, histological examination of wound tissue samples was carried out.
Results. Differences in reduction and change in wound size in the EPO group were more significant than in the standard treatment group.
Conclusions. The experiment demonstrated an improvement in wound healing with EPO treatment compared with standard treatment, which led to a decrease in wound size and a shorter healing period.
References
Nekoui A, Blaise G. Erythropoietin and Nonhematopoietic Effects. The American journal of the Medical Sciences. 2017;353(1):76- 81. DOI: 10.1016/j.amjms.2016.10.009
He J, Zhong X, Zhao L, Gan H. JAK2/STAT3/BMP-2 axis and NF-κB pathway are involved in erythropoietin-induced calcification in rat vascular smooth muscle cells. Clinical and Experimental Nephrology. 2019;23(4):501–512. DOI: 10.1007/s10157-018-1666-z
Kimáková P, Solar P, Solarova Z, et al. Erythropoietin and Its Angiogenic Activity. Int. J. Mol. Sci. 2017;18(7):1519. DOI.10.3390/ ijms18071519
Hameed Al-Sarraf, Malatiali S, Al-Awadi M, Redzic Z. Effects of erythropoietin on astrocytes and brain endothelial cells in primary culture during anoxia depend on simultaneous signaling by other cytokines and on duration of anoxia. Neurochem Int. 2018;113:34-45. DOI. 10.1016/j.neuint.2017.11.014
Hofer M, Hoferova Z, Falk M. Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines? Int. J. Mol. Sci. 2017;18(7):1385. DOI. 10.3390/ijms18071385
Ferozepurwalla Z, Marzan J, Thielemans L, Birdsey G. Molecular and Cellular Mechanisms of Angiogenesis. Heart of the Matter, 2005. P. 219-226
Chin Chai Y, Mendes LM, et al. Fine-tuning pro-angiogenic effects of cobalt for simultaneous enhancement of vascular endothelial growth factor secretion and implant neovascularization. Acta Biomaterialia. 2018;72:447-460. DOI. 10.1016/j.actbio.2018.03.048
Chamorro ME, Maltaneri R, Schiappacasse A, et al. Role of protein tyrosine phosphatase 1B (PTP1B) in the increased sensitivity of endothelial cells to a promigratory effect of erythropoietin in an inflammatory environment. Biol Chem. 2020;401(10):1167-1180. DOI: 10.1515/hsz-2020-0136
Yaghobee S, Rouzmeh N, Aslroosta H, Mahmoodi S, et al. Effect of Topical Erythropoietin (EPO) on palatal wound healing subsequent to Free Gingival Grafting (FGG). Braz Oral Res. 2018;32:e55. DOI. 10.1590/1807-3107bor-2018.vol32.0055
Bikfalvi A. History and conceptual developments in vascular biology and angiogenesis research: a personal view. Angiogenesis. 2017;20(4):463–478. DOI: 10.1007/s10456-017-9569-2
Aguilar-Cazareset D, Chavez-Dominguez R, Carlos-Reyes A, et al. Contribution of Angiogenesis to Inflammation and Cancer. Front. Oncol. 2019;9:1399. DOI. 10.3389/fonc.2019.01399
Huan Ting Ong, Rodney J Dilley. Novel non-angiogenic role for mesenchymal stem cell-derived vascular endothelial growth factor on keratinocytes during wound healing. Cytokine Growth Factor Rev. 2018;44:69-79. DOI. 10.1016/j.cytogfr.2018.11.002
Slukvin II, Kumar A. The mesenchymoangioblast, mesodermal precursor for mesenchymal and endothelial cells. Cell Mol Life Sci. 2018;75(19):3507–3520. DOI: 10.1007/s00018-018-2871-3
Fukui K, Shinozaki Y, Kobayashi H, Deai K, et al. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor. Eur J Pharmacol. 2019;859:172532. DOI. 10.1016/j.ejphar.2019.172532
